Using microemulsion formulations for oral drug delivery of therapeutic peptides

Abstract Peptide drugs are increasingly becoming a very important class of therapeutic agents with the rapid advances in the field of biotechnology engineering. However, these drugs are generally not suitable for oral administration. In this review, the main physico-chemical and biopharmaceutical characteristics of peptides are summarized. The obstacles to peptide drug absorption and the different possibilities for solving these difficulties are listed. Results using this formulation approach for oral drug delivery of peptides are apparently promising with some specific peptides such as cyclosporin. Various mechanisms are only beginning to be understood and further investigations need to be performed in this area to explain the results obtained with some peptides.

[1]  V. Stella,et al.  Factors affecting the lymphatic transport of penclomedine (NSC-338720), a lipophilic cytotoxic drug: Comparison to DDT and hexachlorobenzene , 1992 .

[2]  J. B. Bree,et al.  Safety and steady‐tate pharmacokinetics of a new oral formulation of cyclosporin A in renal transplant patients , 1994, Transplant international : official journal of the European Society for Organ Transplantation.

[3]  W. Higuchi,et al.  Advancing quantitative and mechanistic approaches in interfacing gastrointestinal drug absorption studies in animals and humans , 1983 .

[4]  P. Kovar,et al.  Discovery of a peptide-based renin inhibitor with oral bioavailability and efficacy. , 1992, Science.

[5]  V. H. Lee.  Protease inhibitors and penetration enhancers as approaches to modify peptide absorption , 1990 .

[6]  M. Borkovec.  Phenomenological theories of globular microemulsions. , 1992, Advances in colloid and interface science.

[7]  W A Ritschel,et al.  Microemulsions for improved peptide absorption from the gastrointestinal tract. , 1991, Methods and findings in experimental and clinical pharmacology.

[8]  T. Wieland,et al.  The World of Peptides: A Brief History of Peptide Chemistry , 1991 .

[9]  D. McCarthy,et al.  Nanosphere and microsphere uptake via Peyer's patches: observation of the rate of uptake in the rat after a single oral dose , 1992 .

[10]  V. Lee.  Oral Route of Peptide and Protein Drug Delivery , 1995 .

[11]  P. Couvreur,et al.  Nano- and microparticles for the delivery of polypeptides and proteins , 1993 .

[12]  T. Hoar,et al.  Transparent Water-in-Oil Dispersions: the Oleopathic Hydro-Micelle , 1943, Nature.

[13]  G. Yee.  Dosage Forms of Cyclosporine , 1991, Pharmacotherapy.

[14]  V. Lee.  Enzymatic barriers to peptide and protein absorption. , 1988, Critical reviews in therapeutic drug carrier systems.

[15]  P. Artursson,et al.  Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. , 1991, Biochemical and biophysical research communications.

[16]  R. Venkataramanan,et al.  Clinical Pharmacokinetics of Cyclosporin , 1986, Clinical Pharmacokinetics.

[17]  Wood Jf.  Liposomes for oral administration of drugs. , 1985 .

[18]  A. Banga,et al.  Systemic delivery of therapeutic peptides and proteins , 1988 .

[19]  B. Kahan.  Drug therapy: cyclosporine , 1989 .

[20]  D. Breimer,et al.  Intestinal drug absorption enhancement: an overview. , 1989, Pharmacology & therapeutics.

[21]  D. Wall,et al.  (D) Routes of delivery: Case studies , 1992 .

[22]  M. Morishita,et al.  Novel oral microspheres of insulin with protease inhibitor protecting from enzymatic degradation , 1992 .

[23]  T. Kissel,et al.  Enhancement of the oral absorption of cyclosporin in man. , 1992, British journal of clinical pharmacology.

[24]  B. Aungst.  Novel formulation strategies for improving oral bioavailability of drugs with poor membrane permeation or presystemic metabolism. , 1993, Journal of pharmaceutical sciences.

[25]  W. Curatolo,et al.  C) Means to enhance penetration , 1992 .

[26]  W. Ritschel,et al.  Development of a colonic release capsule dosage form and the absorption of insulin. , 1992, Methods and findings in experimental and clinical pharmacology.

[27]  J. Samanen.  Biomedical Polypeptides — A Wellspring of Pharmaceuticals , 1985 .

[28]  J. Kovarik,et al.  Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. , 1994, Journal of pharmaceutical sciences.

[29]  D. Crommelin,et al.  Comparison of four experimental techniques for studying drug absorption kinetics in the anesthetized rat in situ. , 1986, Journal of pharmaceutical sciences.

[30]  A. Patchett,et al.  Recent developments in the design of angiotensin‐converting enzyme inhibitors , 1985, Medicinal research reviews.

[31]  R. Conradi,et al.  Evidence for a polarized efflux system for peptides in the apical membrane of Caco-2 cells. , 1993, Biochemical and biophysical research communications.

[32]  G. Amidon,et al.  Characterization of the intestinal transport parameters for small peptide drugs , 1990 .

[33]  S. Lynch,et al.  Enhancement of human calcitonin absorption across the rat colon in vivo , 1994 .

[34]  N. Yokoo,et al.  Promoting effect of the new chymotrypsin inhibitor FK‐448 on the intestinal absorption of insulin in rats and dogs , 1985, The Journal of pharmacy and pharmacology.

[35]  N. Bunnett,et al.  Catabolism of substance P in the stomach wall of the rat. , 1985, Life sciences.

[36]  J. Wood,et al.  Synthesis and biological activity of some transition-state inhibitors of human renin. , 1988, Journal of medicinal chemistry.

[37]  C. Samyn,et al.  Azo polymers for colon-specific drug delivery. II: Influence of the type of azo polymer on the degradation by intestinal microflora , 1993 .